- call +1-201-465-4211
- email sales@mrinsights.biz
Diabetic Macular Edema (DME) is a leading cause of blindness among the working age population in most developed countries. DME is one of the major complications of diabetes and DME patients utilise significantly higher healthcare resources than non-DME diabetic patients.
Scope of the Report:
This report focuses on the Diabetic Macular Edema Drug in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Western Europe is expected to be the most lucrative market for diabetic macular edema, with market attractiveness index of 2.7.
The worldwide market for Diabetic Macular Edema Drug is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Novartis
Bayer
Allergan
Hoffman-La Roche
Alimera
Valeant
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Intravitreal Injections
Intravitreal Implants
Market Segment by Applications, can be divided into
Anti-VEGF
Corticosteroids
Others
There are 15 Chapters to deeply display the global Diabetic Macular Edema Drug market.
Chapter 1, to describe Diabetic Macular Edema Drug Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Diabetic Macular Edema Drug, with sales, revenue, and price of Diabetic Macular Edema Drug, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Diabetic Macular Edema Drug, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Diabetic Macular Edema Drug market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Diabetic Macular Edema Drug sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Diabetic Macular Edema Drug Introduction
1.2 Market Analysis by Type
1.2.1 Intravitreal Injections
1.2.2 Intravitreal Implants
1.3 Market Analysis by Applications
1.3.1 Anti-VEGF
1.3.2 Corticosteroids
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Novartis
2.1.1 Business Overview
2.1.2 Diabetic Macular Edema Drug Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Novartis Diabetic Macular Edema Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Bayer
2.2.1 Business Overview
2.2.2 Diabetic Macular Edema Drug Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Bayer Diabetic Macular Edema Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Allergan
2.3.1 Business Overview
2.3.2 Diabetic Macular Edema Drug Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Allergan Diabetic Macular Edema Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Hoffman-La Roche
2.4.1 Business Overview
2.4.2 Diabetic Macular Edema Drug Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Hoffman-La Roche Diabetic Macular Edema Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Alimera
2.5.1 Business Overview
2.5.2 Diabetic Macular Edema Drug Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Alimera Diabetic Macular Edema Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Valeant
2.6.1 Business Overview
2.6.2 Diabetic Macular Edema Drug Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Valeant Diabetic Macular Edema Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Diabetic Macular Edema Drug Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Diabetic Macular Edema Drug Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Diabetic Macular Edema Drug Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Diabetic Macular Edema Drug Manufacturer Market Share in 2017
3.3.2 Top 6 Diabetic Macular Edema Drug Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Diabetic Macular Edema Drug Market Analysis by Regions
4.1 Global Diabetic Macular Edema Drug Sales, Revenue and Market Share by Regions
4.1.1 Global Diabetic Macular Edema Drug Sales and Market Share by Regions (2013-2018)
4.1.2 Global Diabetic Macular Edema Drug Revenue and Market Share by Regions (2013-2018)
4.2 North America Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
4.3 Europe Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
4.5 South America Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
5 North America Diabetic Macular Edema Drug by Countries
5.1 North America Diabetic Macular Edema Drug Sales, Revenue and Market Share by Countries
5.1.1 North America Diabetic Macular Edema Drug Sales and Market Share by Countries (2013-2018)
5.1.2 North America Diabetic Macular Edema Drug Revenue and Market Share by Countries (2013-2018)
5.2 United States Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
5.3 Canada Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
5.4 Mexico Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
6 Europe Diabetic Macular Edema Drug by Countries
6.1 Europe Diabetic Macular Edema Drug Sales, Revenue and Market Share by Countries
6.1.1 Europe Diabetic Macular Edema Drug Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Diabetic Macular Edema Drug Revenue and Market Share by Countries (2013-2018)
6.2 Germany Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
6.3 UK Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
6.4 France Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
6.5 Russia Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
6.6 Italy Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
7 Asia-Pacific Diabetic Macular Edema Drug by Countries
7.1 Asia-Pacific Diabetic Macular Edema Drug Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Diabetic Macular Edema Drug Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Diabetic Macular Edema Drug Revenue and Market Share by Countries (2013-2018)
7.2 China Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
7.3 Japan Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
7.4 Korea Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
7.5 India Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
8 South America Diabetic Macular Edema Drug by Countries
8.1 South America Diabetic Macular Edema Drug Sales, Revenue and Market Share by Countries
8.1.1 South America Diabetic Macular Edema Drug Sales and Market Share by Countries (2013-2018)
8.1.2 South America Diabetic Macular Edema Drug Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
8.3 Argentina Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
8.4 Colombia Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
9 Middle East and Africa Diabetic Macular Edema Drug by Countries
9.1 Middle East and Africa Diabetic Macular Edema Drug Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Diabetic Macular Edema Drug Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Diabetic Macular Edema Drug Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
9.3 UAE Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
9.4 Egypt Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
9.5 Nigeria Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
9.6 South Africa Diabetic Macular Edema Drug Sales and Growth Rate (2013-2018)
10 Global Diabetic Macular Edema Drug Market Segment by Type
10.1 Global Diabetic Macular Edema Drug Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Diabetic Macular Edema Drug Sales and Market Share by Type (2013-2018)
10.1.2 Global Diabetic Macular Edema Drug Revenue and Market Share by Type (2013-2018)
10.2 Intravitreal Injections Sales Growth and Price
10.2.1 Global Intravitreal Injections Sales Growth (2013-2018)
10.2.2 Global Intravitreal Injections Price (2013-2018)
10.3 Intravitreal Implants Sales Growth and Price
10.3.1 Global Intravitreal Implants Sales Growth (2013-2018)
10.3.2 Global Intravitreal Implants Price (2013-2018)
11 Global Diabetic Macular Edema Drug Market Segment by Application
11.1 Global Diabetic Macular Edema Drug Sales Market Share by Application (2013-2018)
11.2 Anti-VEGF Sales Growth (2013-2018)
11.3 Corticosteroids Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Diabetic Macular Edema Drug Market Forecast (2018-2023)
12.1 Global Diabetic Macular Edema Drug Sales, Revenue and Growth Rate (2018-2023)
12.2 Diabetic Macular Edema Drug Market Forecast by Regions (2018-2023)
12.2.1 North America Diabetic Macular Edema Drug Market Forecast (2018-2023)
12.2.2 Europe Diabetic Macular Edema Drug Market Forecast (2018-2023)
12.2.3 Asia-Pacific Diabetic Macular Edema Drug Market Forecast (2018-2023)
12.2.4 South America Diabetic Macular Edema Drug Market Forecast (2018-2023)
12.2.5 Middle East and Africa Diabetic Macular Edema Drug Market Forecast (2018-2023)
12.3 Diabetic Macular Edema Drug Market Forecast by Type (2018-2023)
12.3.1 Global Diabetic Macular Edema Drug Sales Forecast by Type (2018-2023)
12.3.2 Global Diabetic Macular Edema Drug Market Share Forecast by Type (2018-2023)
12.4 Diabetic Macular Edema Drug Market Forecast by Application (2018-2023)
12.4.1 Global Diabetic Macular Edema Drug Sales Forecast by Application (2018-2023)
12.4.2 Global Diabetic Macular Edema Drug Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Diabetic Macular Edema Drug Picture
Table Product Specifications of Diabetic Macular Edema Drug
Figure Global Sales Market Share of Diabetic Macular Edema Drug by Ty
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
